Article
Evaluation of a CYP2C19 genotype panel on the GenMark eSensor® platform and the comparison to the Autogenomics Infiniti™ and Luminex CYP2C19 panels.
Clinica chimica acta; international journal of clinical chemistry - 12 May 2011
Lee Christine C, McMillin Gwendolyn A, Babic Nikolina, Melis Roberta, Yeo Kiang-Teck J
Abstract excerpt
BACKGROUND: CYP2C19 variants have been demonstrated to play an important role in determining response to clopidogrel and outcomes while on clopidogrel therapy. Predicting patient response through pre-therapeutic genotyping may therefore guide selection of antiplatelet therapy. METHODS: CYP2C19 genotypes were determined for 111 samples with the eSensor and compared with the Autogenomics expanded CYP2C19 panel,...
Topics
Join the communities discussing this publication.